Physician profile
Edward Spellman
NPI 1558303727
$1,031.06
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $994 · 2021: $12.23 · 2022: $24.95.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $278.90 | 2019 | |
| Alexion Pharmaceuticals, INC. | $186.67 | 2019 | |
| Ucb, INC. | $145.17 | 2019 | |
| Amgen INC. | $144.27 | 2019 | |
| Lilly USA, LLC | $99.96 | 2019 | |
| Mdd US Operations, LLC | $64.57 | 2019 | |
| Abbvie INC. | $37.18 | 2021-2022 | |
| Kyowa Kirin, INC. | $26.09 | 2019 | |
| Biogen, INC. | $20.73 | 2019 | |
| Novartis Pharmaceuticals Corporation | $16.73 | 2019 | |
| Neurocrine Biosciences, INC. | $10.79 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Spellman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.